XLIFE-SCIENCES-AG
10.6.2021 08:08:07 CEST | Business Wire | Press release
Xlife Sciences AG (XLS DE): Breakthrough in Drug Development First available holistic medical drug to treat Covid-19 and flu viruses As a project company of Xlife Sciences AG (XLS DE), inflamed pharma GmbH has developed a revolutionary and holistic therapeutic approach to treat both SARS-CoV-2 and flu viruses. The patented active substance ProcCluster(R) reduces the viral load by 90% and acts against infection-related inflammatory processes without developing a resistance. It is already used on humans. The active pharmaceutical ingredient ProcCluster(R) developed by inflamed pharma GmbH is membrane permeable and is based on the active ingredient procaine. It acts both locally as well as systemically and is characterized by a wide range of applications in inflammatory diseases. ProcCluster(R) is already used for various prescription drugs for humans. In various case studies, renowned medical doctors have now been able to successfully demonstrate the effectiveness in the treatment of Covid-19 and Long-Covid patients. In studies with various cell lines, especially lung cells, the active ingredient was able to reduce the viral load by 90% in an early phase and effectively inhibit inflammation in a later phase. These effects can be transferred to other RNA viruses. Oliver R. Baumann, CEO of Xlife Sciences AG, comments: "ProcCluster(R) has enormous market potential because, in contrast to other active ingredients, both the inflammatory processes and the viral load in the body are significantly reduced. This means that it can be used at different points in time during the course of the Covid-19 disease". It is of inestimable value that this active ingredient is already produced by inflamed pharma GmbH in high quality at low cost. "Another key advantage compared to vaccines and antibodies is that ProcCluster(R) does not lead to resistance development and can also be used against virus mutants", continues Baumann. In addition, ProcCluster(R) has a stimulating effect on the microcirculation, which is particularly important for Long-Covid patients. So far, no negative side effects have been observed either. According to the management of Xlife, they are already in various discussions with possible industrial partners in order to have ProcCluster(R) industrially manufactured. The aim is for the active ingredient to be licensed out as quickly as possible. About Xlife Sciences AG Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch
Language: |
English |
Company: |
Xlife Sciences AG Klausstrasse 19 8008 Zürich Switzerland |
Phone: |
0041 44 385 84 60 |
E-mail: |
|
Internet: |
|
ISIN: |
CH0461929603 |
WKN: |
A2PK6Z |
Listed: |
Regulated Unofficial Market in Frankfurt, Munich |
| EQS News ID: | 1206317 |
| End of Announcement | DGAP News Service |
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005992/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System1.4.2026 15:30:00 CEST | Press release
VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company’s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE approval enables initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation (TR). “This is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,” said Mike Buck, Chief Executive Officer. “Our focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.” Significant unmet clinical needs exist in the
NetJets Introduces State-of-the-Art, Exclusive-Use Terminal in Augusta, Georgia1.4.2026 15:05:00 CEST | Press release
New facility set to elevate the experience for customers during golf’s most celebrated event—and beyond NetJets, the global leader in private aviation, is well underway on its development of a new exclusive-use terminal at Augusta Regional Airport (AGS). This state-of-the-art facility represents a significant investment in the region and reinforces NetJets’ commitment to delivering unparalleled experiences for its customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330125414/en/ NetJets to open a new, exclusive-use terminal at Augusta Regional Airport (AGS). Guests arriving this April for golf’s most iconic championship will witness the construction in progress, including the finished ramp and foundational walls of what will soon become a full-service terminal. The private ramp, offering 432,000 square feet of space for aircraft parking, will be completed in time for the 2026 golf tournament. “Augusta is a key desti
Visa Unveils New Services to Modernize Dispute Resolution Process1.4.2026 15:00:00 CEST | Press release
Fraudulent disputes and administrative inefficiencies drive billions in avoidable economic costsSix new and enhanced dispute resolution tools utilize AI and proprietary technology to help provide issuers, acquirers and merchants with increased visibility into costly fraud expenses Visa (NYSE: V), a global leader in digital payments, today announced six new dispute resolution tools designed to reduce the billions of dollars lost annually to inefficient, outdated dispute processes. The expanded suite of dispute resolution services is being designed to help merchants and financial institutions cut administrative costs, reduce fraud-related losses and redirect those resources toward growth, innovation and customer experience. Disputes remain one of the most persistent friction points in commerce, driving rising costs for merchants and financial institutions while simultaneously leaving consumers frustrated and confused. In 2025, Visa processed 106 million disputes globally, a 35% increase
Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement1.4.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced first quarter debt reduction activities and a recent amendment to its credit agreement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401160360/en/ Rimini Street Announces Debt Reduction and Amendment to its Credit Agreement Debt reduction activities during the first quarter of 2026 totaled $10.9 million, reducing the Company’s outstanding term loan to $58.4 million as of March 31, 2026. The Company’s credit agreement was amended effective as of March 27, 2026 to increase to $20.0 million the value of Company common stock that could be repurchased per annum, beginning with the Company’s 2026 fiscal year and for each fiscal year thereafter, with a revised total of $50.0 million in permitted stock repurchases from the period beginning January
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware1.4.2026 15:00:00 CEST | Press release
New partnership delivers sub-100ms, fully on-device avatars — unlocking scalable, lifelike AI characters for games, film and interactive media Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital human systems running entirely on standard CPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401782320/en/ Rapport and Neuphonic announce a partnership to deliver next-generation conversational AI experiences. The collaboration combines Neuphonic’s ultra-low latency text-to-speech technology with Rapport, an interactive AI avatar role play platform powered by production-proven real-time facial and full-body animation technology from Speech Graphics, used in video games such as Call of Duty, The Last of Us Part II and Hogwarts Legacy. Together, the system generates natural voice, perfectly synchronised
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom